Ghrelin receptors in the heart, kidney, and blood vessels provide proof of ghrelin effect on blood pressure. Aim: This research was conducted to compare the effect of ghrelin on blood pressure in normotensive and hypertensive rats with other common antihypertensive drugs. Methods: 72 male albino rats were distributed into 9 groups; 1st group: control, 2nd group: Ghrelin treated, 3rd group: Uninephrectomized (UNX) rats, 4th group: UNX + Ghrelin treated (UNX+Gh) rats, 5th group: DOCA-salt Hypertensive, 6th group: DOCA-salt Hypertensive + Ghrelin (DOCA+Gh), 7th group: DOCA-salt Hypertensive + Ca channel Blocker, 8th group: DOCA-salt Hypertensive + Angiotensin Converting Enzyme Inhibitor, 9th group: DOCA-salt Hypertensive + Selective Beta 1 receptor Blocker. Results: blood pressures (diastolic and systolic) were decreased insignificantly (P>0.05) in ghrelin treated group in comparison with control group and significantly (P < 0.05) in (UNX+Gh) group in comparison with UNX group. In (DOCA+Gh) group, ghrelin decreased systolic blood pressure significantly (P<0.05 compared with UNX group and highly significantly (P<0.0001) compared with DOCA group in all weeks. DOCA+Gh group was Significantly different (p<0.05) from DOCA+ Nifidipine, DOCA+ ACEI and DOCA+ B Blocker groups. Conclusion: ghrelin produced a significant inhibitory effect on systolic and diastolic blood pressure, this effect is comparable to that produced by calcium channel blockers and less than that produced by ACEI and B blockers. Indication of ghrelin as a new antihypertensive line for treatment of hypertension in chronic use needs further studies on human for longer periods.